Randomized comparison of Sequential therapies with Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma.

Trial Profile

Randomized comparison of Sequential therapies with Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Mar 2017

At a glance

  • Drugs Sunitinib (Primary) ; Sorafenib
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms CROSS-J-RCC
  • Most Recent Events

    • 20 Mar 2017 Status changed from active, no longer recruiting to completed, according to results presented at the 2017 Genitourinary Cancers Symposium.
    • 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium
    • 01 Feb 2014 Primary endpoint 'Progression-free-survival-duration' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top